These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36764389)

  • 1. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.
    Canévet M; Pruvost-Couvreur M; Morvan M; Badic B; Brousse-Potocki J; Kermarrec T; Bouzeloc S; Nousbaum JB; Robaszkiewicz M; Reboux N; Quénéhervé L
    Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102093. PubMed ID: 36764389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia].
    Lu M; Chen HD; Liu CC; Zhang YH; Wei LP; Lyu ZY; Ren JS; Shi JF; Zou SM; Li N; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2104-2111. PubMed ID: 33378824
    [No Abstract]   [Full Text] [Related]  

  • 9. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location.
    Niedermaier T; Tikk K; Gies A; Bieck S; Brenner H
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2920-2928.e6. PubMed ID: 31988043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.
    Kooyker A; de Jonge L; Toes-Zoutendijk E; Spaander M; van Vuuren H; Kuipers E; van Kemenade F; Ramakers C; Dekker E; Nagtegaal I; van Leerdam M; Lansdorp-Vogelaar I
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3424-3432.e2. PubMed ID: 37619823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features of Fecal Immunochemical Test-Negative Colorectal Lesions based on Colorectal Cancer Screening among Asymptomatic Participants in Their 50s.
    Suto S; Matsuzaka M; Sawaya M; Sakuraba H; Mikami T; Matsuda T; Fujii T; Saito Y; Hotta K; Ikematsu H; Hanabata N; Saito H; Yoshida S; Fukuda S
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2325-2332. PubMed ID: 35901338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.
    Toes-Zoutendijk E; Kooyker AI; Dekker E; Spaander MCW; Opstal-van Winden AWJ; Ramakers C; Buskermolen M; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Velthuysen MF; Thomeer MGJ; van Veldhuizen H; van Ballegooijen M; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I;
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1493-1500. PubMed ID: 31442598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of the test performance of self-administered qualitative vs. laboratory-based quantitative fecal immunochemical tests in detecting colorectal neoplasm.
    Lu M; Zhang YH; Lu B; Cai J; Liu CC; Chen HD; Dai M
    Chin Med J (Engl); 2021 May; 134(11):1335-1344. PubMed ID: 34039863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proportions and characteristics of interval cancer in annual fecal immunochemical test screening and postcolonoscopy colorectal cancer: Results from a Japanese multicenter prospective study using questionnaires, the C-DETECT study.
    Sekiguchi M; Kishida Y; Ikematsu H; Konno M; Mizuguchi Y; Hotta K; Imai K; Ito S; Takada K; Shiomi A; Yasui H; Tsukamoto S; Hirano H; Kobayashi N; Saito Y; Inaba A; Shinmura K; Konishi J; Ozawa H; Fujita S; Murakami Y; Matsuda T
    Dig Endosc; 2024 Oct; 36(10):1140-1151. PubMed ID: 38433322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.